HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Money

Daiichi Sankyo takes $610M profit hit linked to ADC manufacturing overbuild

Daiichi Sankyo is poised to report significantly lower full-year profit for fiscal year 2025, primarily due to a $610 million hit linked to its precautionary antibody-drug conjugate manufacturing strategy.

By FiercePharma · May 11, 2026 · via FiercePharma
Daiichi Sankyo takes $610M profit hit linked to ADC manufacturing overbuild

Image: FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

Tags
moneyformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
Odyssey’s CEO sees $304M IPO as chance to create a ‘little large pharma’
MoneyFierceBiotech ↗
Odyssey’s CEO sees $304M IPO as chance to create a ‘little large pharma’
Odyssey Therapeutics has become the latest biotech to voyage to the public markets via an upsized $304 million…
May 11, 2026
Optimi Health’s IPO Rides Psychedelics Policy Shift
MoneyBriefing
Optimi Health’s IPO Rides Psychedelics Policy Shift
Vancouver’s Optimi Health launched a 2.5M-share IPO just as U.S. policy momentum boosts psychedelics research,…
May 11, 2026
CSL sinks to nine-year low on revenue warning, $5B write-down
MoneyEndpoints News ↗
CSL sinks to nine-year low on revenue warning, $5B write-down
CSL's stock hit its lowest price since early 2017 on Monday after it lowered its full-year revenue guidance by…
May 11, 2026